文献速递胸部神经CTMR

CT与MRI双模态影像组学预测伴脑转移的非小细胞肺癌患者EGFR状态:一项多中心研究

CT and MRI bimodal radiomics for predicting EGFR status in NSCLC patients with brain metastases: A multicenter study.
PubMed 文献 · Eur J Radiol · 2024-11-28

本研究纳入三个独立中心共309例伴脑转移的非小细胞肺癌患者,基于胸部CT与脑MRI提取影像组学特征构建双模态列线图预测EGFR突变状态。双模态列线图在内测组AUC为0.866(95%CI 0.778-0.950),在外测组AUC为0.818(95%CI 0.691-0.938),校准与区分度良好。

要点

  • 双模态影像组学列线图整合胸部CT与脑MRI特征,用于预测伴脑转移NSCLC患者的EGFR突变状态。
  • 内测组AUC 0.866(95%CI 0.778-0.950),外测组AUC 0.818(95%CI 0.691-0.938)。
  • CT选用对比增强XGBoost模型,MRI选用T2WI+T1CE随机森林模型,两者均为EGFR突变的独立预测因子。

核心结论

  • 胸部CT与脑MRI双模态影像组学列线图可在必要材料获取受限的患者中及时、准确地评估EGFR突变可能性,弥补血浆测序的不足并促进精准医学发展。

研究设计与样本

  • 多中心研究,共纳入三个独立中心309例伴脑转移的非小细胞肺癌患者;中心I患者按7:3随机分为训练组与内测组,中心II与中心III共同组成外测组;对每例患者胸部CT与脑MRI图像进行配准及单模态内序列组合,预处理后从每个单序列提取1037个影像组学特征,采用六种机器学习算法分别构建CT与MRI影像组学标签。

诊断标准与关键数值

  • CT对比增强XGBoost模型与MRI T2WI+T1CE随机森林模型被选为分别代表原发灶与脑转移灶的影像组学标签,两者均为EGFR突变的独立预测因子;双模态列线图内测组AUC 0.866(95%CI 0.778-0.950),外测组AUC 0.818(95%CI 0.691-0.938)。

临床应用与阅片要点

  • 作者认为该双模态影像组学列线图可在必要材料获取受限的患者中及时、准确地评估EGFR突变可能性,弥补血浆测序的不足并促进精准医学发展。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND: Leveraging the radiomics information from non-small cell lung cancer (NSCLC) primary lesion and brain metastasis (BM) to develop and validate a bimodal radiomics nomogram that can accurately predict epidermal growth factor receptor (EGFR) status.

METHODS: A total of 309 NSCLC patients with BM from three independent centers were recruited. Among them, the patients of Center I were randomly allocated into the training and internal test cohorts in a 7:3 ratio. Meanwhile, the patients from Center Ⅱ and Center Ⅲ collectively constitute the external test cohort. All chest CT and brain MRI images of each patient were obtained for image registration and sequence combination within a single modality. After image preprocessing, 1037 radiomics features were extracted from each single sequence. Six machine learning algorithms were used to construct radiomics signatures for CT and MRI respectively. The best CT and MRI radiomics signatures were fitted to establish the bimodal radiomics nomogram for predicting the EGFR status.

RESULTS: The contrast-enhanced (CE) eXtreme gradient boosting (XG Boost) and T2-weighted imaging (T2WI) + T1-weighted contrast-enhanced imaging (T1CE) random forest models were chosen as the radiomics signature representing primary lesion and BM. Both models were found to be independent predictors of EGFR mutation. The bimodal radiomics nomogram, which incorporated CT radiomics signature and MRI radiomics signature, demonstrated a good calibration and discrimination in the internal test cohort [area under curve (AUC), 0.866; 95 % confidence intervals (CI), 0.778-0.950) and the external test cohort (AUC, 0.818; 95 % CI, 0.691-0.938).

CONCLUSIONS: Our CT and MRI bimodal radiomics nomogram could timely and accurately evaluate the likelihood of EGFR mutation in patients with limited access to necessary materials, thus making up for the shortcoming of plasma sequencing and promoting the advancement of precision medicine.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ouyang Z, Zhang G, He S, et al. CT and MRI bimodal radiomics for predicting EGFR status in NSCLC patients with brain metastases: A multicenter study. Eur J Radiol. 2024. PMID: 39647269. doi:10.1016/j.ejrad.2024.111853

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。